22nd Century Group, Inc. (NASDAQ:XXII – Get Rating) insider John Franzino sold 20,324 shares of the business’s stock in a transaction dated Tuesday, June 14th. The stock was sold at an average price of $1.69, for a total value of $34,347.56. Following the transaction, the insider now directly owns 405,574 shares of the company’s stock, valued at approximately $685,420.06. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
22nd Century Group stock opened at $1.73 on Friday. The firm has a 50 day moving average price of $1.88. 22nd Century Group, Inc. has a 12 month low of $1.42 and a 12 month high of $4.98.
22nd Century Group (NASDAQ:XXII – Get Rating) last posted its quarterly earnings results on Thursday, May 5th. The biotechnology company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01. 22nd Century Group had a negative return on equity of 43.44% and a negative net margin of 109.97%. During the same period in the previous year, the business posted ($0.03) earnings per share. Equities research analysts expect that 22nd Century Group, Inc. will post -0.21 earnings per share for the current year.
Institutional investors and hedge funds have recently modified their holdings of the company. Walleye Capital LLC acquired a new position in shares of 22nd Century Group in the 4th quarter worth approximately $32,000. Private Advisor Group LLC acquired a new position in shares of 22nd Century Group in the 4th quarter worth approximately $32,000. AE Wealth Management LLC acquired a new position in shares of 22nd Century Group in the 1st quarter worth approximately $31,000. Capital Investment Advisory Services LLC acquired a new position in shares of 22nd Century Group in the 4th quarter worth approximately $42,000. Finally, Carolinas Wealth Consulting LLC raised its holdings in shares of 22nd Century Group by 83.8% in the 4th quarter. Carolinas Wealth Consulting LLC now owns 13,837 shares of the biotechnology company’s stock worth $43,000 after buying an additional 6,309 shares in the last quarter. 28.18% of the stock is owned by institutional investors and hedge funds.
About 22nd Century Group (Get Rating)
22nd Century Group, Inc, an agricultural biotechnology company, focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries. It develops very low nicotine content tobacco and cigarette products under the VLN King and VLN Menthol King names; and SPECTRUM research cigarettes for use in independent clinical studies.
Featured Stories
- Get a free copy of the StockNews.com research report on 22nd Century Group (XXII)
- Vuzix Stock Stays Optimistic
- Palo Alto Networks: Pioneering AI in Cybersecurity
- The Analysts Upgrade… Retail Stocks?
- Dividend Stocks and Your Roth IRA
- The Q2 Earnings Season Could Be A Bloodbath
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.